INCOME TAXES (Details Narrative) - USD ($) |
12 Months Ended | |
---|---|---|
Dec. 31, 2024 |
Dec. 31, 2023 |
|
Effective Income Tax Rate Reconciliation [Line Items] | ||
Income tax expense | $ 8,194,000 | |
Operating loss carryforwards, expiration date discription | expire in various amounts starting in 2024 | |
Federal income tax payable | $ 0 | $ 44,000 |
Research and development expense | 1,172,000 | 561,000 |
Research and Development Expense [Member] | ||
Effective Income Tax Rate Reconciliation [Line Items] | ||
Research and development expense | 2,240,000 | $ 2,240,000 |
Domestic Tax Jurisdiction [Member] | ||
Effective Income Tax Rate Reconciliation [Line Items] | ||
Net operating loss carryforwards | 33,470,000 | |
State and Local Jurisdiction [Member] | ||
Effective Income Tax Rate Reconciliation [Line Items] | ||
Net operating loss carryforwards | $ 81,775,000 |
X | ||||||||||
- Definition Operating loss carryforwards, expiration date discription. No definition available.
|
X | ||||||||||
- Definition Amount of deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition Amount of current and deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred national tax expense (benefit) for non-US (United States of America) jurisdiction. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|